Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

San Diego, USA
11995 El Camino Real
Suite 305
San Diego, CA, 92130
USA

People

President and CEO
Board of Directors
Board Director
Board of Directors
Chief Business Officer

Funding

TOTAL $51M
FUNDING TOTAL $51M
Series A, 3/2010
$1.2M
Series B, 8/2012
Morgenthaler Ventures
Kleiner Perkins Caufield & Byers
Technology Partners
$4M
Series B, 12/2012
$21.1M
Series C, 2/2014
GSM Fund
Morgenthaler Ventures
Kleiner Perkins Caufield & Byers
Technology Partners
$24.7M

Tags

Elcelyx Therapeutics

Elcelyx Therapeutics is developing ultra-safe products for weight management and obesity-related metabolic disorders based on the science of nutrient sensing. Elcelyx’ first-in-class Gut Sensory Modulators are delivered directly to the gut where they intensify the body’s natural food-driven signals that trigger a sense of fullness and facilitate glucose regulation. The Elcelyx product candidates, Lovidia for weight management and NewMet for Type 2 diabetes, are composed of active dietary and pharmaceutical ingredients that have been safely used by consumers for decades. Lovidia and NewMet represent reduced-risk, near-term blockbuster opportunities in weight management and diabetes with longer-term opportunities in obesity and prediabetes.

Recent Milestones

Videos

Screenshots

Elcelyx Therapeutics screenshot
Above: Elcelyx Therapeutics
Uploaded: 8/14/12

Sources

  1. SEC (sec.gov) [edit]
  2. Elcelyx Therapeutics Extends Series B Financing for Late-Stage Clinical Programs in Weight Loss and Diabetes (m.prnewswire.com) [edit]
  3. SEC (sec.gov) [edit]
  4. SEC D/A (sec.gov) [edit]
Edit This Page
Last Edited 2/23/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy